← All trials
NCT06046820
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 12, 2024
- Primary completion
- May 31, 2025
- Completion date
- Jun 30, 2025
- First posted
- Sep 21, 2023
- Last posted
- Dec 13, 2023
- Enrollment
- 33
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Inozyme PharmaLead sponsor
- Inozyme PharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.